Research ExplorerPublicationsCD169/SIGLEC1 is expressed on circulating monocytes in COVID...

CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity

Standard

CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. / Doehn, Jan-Moritz; Tabeling, Christoph; Biesen, Robert; Saccomanno, Jacopo; Madlung, Elena; Pappe, Eva; Gabriel, Frieder; Kurth, Florian; Meisel, Christian; Corman, Victor M; Hanitsch, Leif G; Treskatsch, Sascha; Heim, Kathrin; Stegemann, Miriam S; Ruwwe-Glösenkamp, Christoph; Müller-Redetzky, Holger C; Uhrig, Alexander; Somasundaram, Rajan; Spies, Claudia; von Bernuth, Horst; Hofmann, Jörg; Drosten, Christian; Suttorp, Norbert; Witzenrath, Martin; Sander, Leif E; Hübner, Ralf-Harto.

In: INFECTION, Vol. 49, No. 4, 08.2021, p. 757-762.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Doehn, J-M, Tabeling, C, Biesen, R, Saccomanno, J, Madlung, E, Pappe, E, Gabriel, F, Kurth, F, Meisel, C, Corman, VM, Hanitsch, LG, Treskatsch, S, Heim, K, Stegemann, MS, Ruwwe-Glösenkamp, C, Müller-Redetzky, HC, Uhrig, A, Somasundaram, R, Spies, C, von Bernuth, H, Hofmann, J, Drosten, C, Suttorp, N, Witzenrath, M, Sander, LE & Hübner, R-H 2021, 'CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity', INFECTION, vol. 49, no. 4, pp. 757-762. https://doi.org/10.1007/s15010-021-01606-9

APA

Doehn, J-M., Tabeling, C., Biesen, R., Saccomanno, J., Madlung, E., Pappe, E., Gabriel, F., Kurth, F., Meisel, C., Corman, V. M., Hanitsch, L. G., Treskatsch, S., Heim, K., Stegemann, M. S., Ruwwe-Glösenkamp, C., Müller-Redetzky, H. C., Uhrig, A., Somasundaram, R., Spies, C., ... Hübner, R-H. (2021). CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. INFECTION, 49(4), 757-762. https://doi.org/10.1007/s15010-021-01606-9

Vancouver

Doehn J-M, Tabeling C, Biesen R, Saccomanno J, Madlung E, Pappe E et al. CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. INFECTION. 2021 Aug;49(4):757-762. https://doi.org/10.1007/s15010-021-01606-9

Bibtex

@article{30067c33228347e687926d126bbe82ed,
title = "CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity",
abstract = "Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.",
keywords = "Aged, COVID-19/immunology, Female, Hospitalization, Humans, Longitudinal Studies, Male, Middle Aged, Monocytes/immunology, Retrospective Studies, SARS-CoV-2/physiology, Severity of Illness Index, Sialic Acid Binding Ig-like Lectin 1/biosynthesis, Up-Regulation",
author = "Jan-Moritz Doehn and Christoph Tabeling and Robert Biesen and Jacopo Saccomanno and Elena Madlung and Eva Pappe and Frieder Gabriel and Florian Kurth and Christian Meisel and Corman, {Victor M} and Hanitsch, {Leif G} and Sascha Treskatsch and Kathrin Heim and Stegemann, {Miriam S} and Christoph Ruwwe-Gl{\"o}senkamp and M{\"u}ller-Redetzky, {Holger C} and Alexander Uhrig and Rajan Somasundaram and Claudia Spies and {von Bernuth}, Horst and J{\"o}rg Hofmann and Christian Drosten and Norbert Suttorp and Martin Witzenrath and Sander, {Leif E} and Ralf-Harto H{\"u}bner",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = aug,
doi = "10.1007/s15010-021-01606-9",
language = "English",
volume = "49",
pages = "757--762",
journal = "INFECTION",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "4",

}

RIS

TY - JOUR

T1 - CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity

AU - Doehn, Jan-Moritz

AU - Tabeling, Christoph

AU - Biesen, Robert

AU - Saccomanno, Jacopo

AU - Madlung, Elena

AU - Pappe, Eva

AU - Gabriel, Frieder

AU - Kurth, Florian

AU - Meisel, Christian

AU - Corman, Victor M

AU - Hanitsch, Leif G

AU - Treskatsch, Sascha

AU - Heim, Kathrin

AU - Stegemann, Miriam S

AU - Ruwwe-Glösenkamp, Christoph

AU - Müller-Redetzky, Holger C

AU - Uhrig, Alexander

AU - Somasundaram, Rajan

AU - Spies, Claudia

AU - von Bernuth, Horst

AU - Hofmann, Jörg

AU - Drosten, Christian

AU - Suttorp, Norbert

AU - Witzenrath, Martin

AU - Sander, Leif E

AU - Hübner, Ralf-Harto

N1 - © 2021. The Author(s).

PY - 2021/8

Y1 - 2021/8

N2 - Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.

AB - Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Type I interferons are important in the defense of viral infections. Recently, neutralizing IgG auto-antibodies against type I interferons were found in patients with severe COVID-19 infection. Here, we analyzed expression of CD169/SIGLEC1, a well described downstream molecule in interferon signaling, and found increased monocytic CD169/SIGLEC1 expression levels in patients with mild, acute COVID-19, compared to patients with severe disease. We recommend further clinical studies to evaluate the value of CD169/SIGLEC1 expression in patients with COVID-19 with or without auto-antibodies against type I interferons.

KW - Aged

KW - COVID-19/immunology

KW - Female

KW - Hospitalization

KW - Humans

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - Monocytes/immunology

KW - Retrospective Studies

KW - SARS-CoV-2/physiology

KW - Severity of Illness Index

KW - Sialic Acid Binding Ig-like Lectin 1/biosynthesis

KW - Up-Regulation

U2 - 10.1007/s15010-021-01606-9

DO - 10.1007/s15010-021-01606-9

M3 - SCORING: Journal article

C2 - 33825125

VL - 49

SP - 757

EP - 762

JO - INFECTION

JF - INFECTION

SN - 0300-8126

IS - 4

ER -